SPEAKER:
Dr. Fang Wu is a clinical chemist at the Saskatchewan Health Authority in Saskatoon. Currently, she serves as Division Head of Clinical Chemistry in Saskatoon integrated service areas SHA. Dr. Wu is also an Associate Professor and clinical chemistry fellowship program director in the Department of Pathology and Laboratory Medicine at the University of Saskatchewan College of Medicine.
Overview:
This presentation will begin with an overview of the important roles of pharmacogenomics (PGx) testing in advancing personalized drug therapy. It will then focus on the implementation of the DPYD pharmacogenomics program in Saskatchewan, designed to optimize 5-Fluorouracil (5-FU) dosing for cancer patients while minimizing treatment-related toxicity. Furthermore, it will highlight the complementary role of other testing methods, such as phenotype testing, in personalized drug therapy. The presentation will conclude with a discussion of the challenges and considerations faced during the program’s launch.
learning objectives:
At the conclusion of this session, participants will be able to:
1) Understand clinical Pharmacogenomics (PGx) and its role in personalized drug therapy
2) Explain the clinical significance of the DPYD pharmacogenomics program in guiding 5-Fluorouracil (5-FU) dosing and reducing treatment-related toxicity.
3) Explore lab testing methods beyond PGx to enhance the precision of personalized drug therapy.
4) Recognize the challenges and considerations in implementing a pharmacogenomics program and strategies for successful integration into clinical practice.